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ABSTRACT 
Syndecan-1 is a cell surface heparan sulfate proteoglycan expressing on epithelial cells. 
Heparan sulfate (HS) chains on syndecan-1 constitute growth factor attachment sites and 
facilitate growth factors to bind their respective receptors. This binding property of HS chains 
allows syndecan-1 to be involved in various cellular processes. The fine structure of HS 
defines the binding properties of these chains. Sulfatase-1 is one of the enzymes that regulates 
sulfation pattern of HS chains. On the cell membrane syndecan-1 can get shed and the soluble 
proteoglycan can compete with cell surface-bound and might have counteracting roles.  
Malignant mesothelioma (MM) is highly aggressive tumor of mesothelial cells lining the 
serosal cavities. Presence of syndecan-1 on the cell surface of MM is associated with 
favorable prognosis, whereas the decrease of syndecan-1 deteriorates the prognosis. With this 
thesis work, we aimed to disclose syndecan-1 roles and the underlying mechanisms by which 
syndecan-1 affect the behavior of malignant mesothelioma.  
We focused on genes and pathways modulated by syndecan-1 overexpression and silencing 
in a mesothelioma cell line (paper I), and we found out that TGF-β, EGF, VEGF and 
ERK/MAPK pathways were affected in both settings. Syndecan-1 silencing enriched cell 
cycle pathways and syndecan-1 overexpression had the opposite effects. Syndecan-1 
overexpression affected gene expression involved in angiogenesis, adhesion, proliferation, 
cell cycle, migration, interleukins, extracellular matrix proteins and HS modifying enzymes. 
Among the HS modifying enzymes affected by syndecan-1 overexpression, sulfatase-1 gene 
was highly downregulated (paper III). HS content was decreased but overall sulfation was 
increased by syndecan-1 overexpression. Studying downstream signaling molecules showed 
that syndecan-1 affects PI3K and MAPK signaling pathways in mesothelioma, which leads to 
cell cycle arrest at G1. 
Syndecan-1 level was evaluated in two cohorts of patients both in pleural effusions and sera 
(paper II). Syndecan-1 was elevated in malignant effusions than benign conditions and could 
predict malignant disease. In addition, patients with higher levels of syndecan-1 in pleural 
effusion had shorter survival compared to the patients with lower syndecan-1 levels. 
However these effects were not observed with syndecan-1 levels in serum. 
Syndecan-1 overexpression on mesothelioma cells inhibited endothelial cell proliferation, 
migration and tube formation (paper IV). Endothelial cell tube formation was reverted by 
MMP7 silencing, which is one of the important sheddases of syndecan-1. Co-cultured 
HUVEC and mesothelioma cells showed less nuclear Yes-associated protein (YAP) 
expression, which is associated with less migration. The angiogenesis inhibitory effects of 
syndecan-1 overexpressing cells were conducted by both pro- and anti-angiogenic factors 
comprising Angiopoietin-1, FGF-4, HGF, NRG1-β1, TSP-1, TIMP-1 and TGF-β1. VEGF 
levels in pleural effusions from mesothelioma patients correlate to soluble syndecan-1 levels 
and have prognostic value in these patients. Combining shed syndecan-1 and VEGF seemed 
to be better for prognostic evaluation of mesothelioma patients than these factors alone. 
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1 BACKGROUND 
1.1 MALIGNANT MESOTHELIOMA 
1.1.1 Types, aetiology and epidemiology 
Malignant mesothelioma (MM) is a tumor arising from mesothelial cells that cover the lungs 
(pleura), heart (pericardium), abdomen (peritoneum) and a mesothelial remain is seen in the 
testis capsule (tunica vaginalis). The most frequently occurring type is malignant pleural 
mesothelioma (MPM) which accounts for nearly 70% of all mesothelioma cases [1, 2], and it 
is the focus of this thesis.  
The main cause of MM is asbestos exposure. Asbestos is a carcinogenic mineral fiber that has 
been widespreadly used in the past, and has been prohibited nowadays in western countries, 
while its use in countries like China, India and Brazil is higher than ever. However, due to the 
long latency of mesothelioma which is between 20-40 years [1, 3] and differences in the 
prohibition rules of asbestos in various countries, mesothelioma incidence remains an 
increasing problem worldwide [4]. Although 90% of mesothelioma cases are associated with 
asbestos exposure, 10% are thought to develop mesothelioma due to genetic predispositions 
or other asbestos-like materials such as erionite [5], which are other reasons for constant 
prevalence of this disease [6]. In Cappadocia region of Turkey, erionite containing rocks have 
been used in constructing and painting houses. Erionite tumorigenesis has been shown to be 
the strong cause for high incidence of mesotheliomas in this area [5]. 
The incidence of mesothelioma in Western Australia is the highest in the world [7] mainly 
due to the Wittenoom mine. In Europe the highest incidence is found in Great Britain, the 
Netherlands, Malta and Belgium. Sweden is among the countries with intermediate incidence 
rate, with 100 annual cases of mesothelioma [8].  
1.1.2 Pleural effusions 
The pleura consist of a thin flat monolayer of mesothelial cells resting on a basement 
membrane with fibroblast-like progenitor cells underneath. Although mesothelial cells arise 
from the mesoderm and have NCAM (neural cell adhesion molecule) for attachment, i.e., 
classifying these cells as mesenchymal, these mesenchymal cells mimic epithelial cells in 
terms of covering a surface motivating the term “mesothelium” [9, 10]. The pleura cover the 
lungs and chest wall and consist of two layers. The space between these two layers of pleura 
forms the pleural cavity, which contains normally only a minute volume of fluid and low 
cellular content, including macrophages, mesothelial cells, and lymphocytes (Figure 1) [11]. 
This fluid aids lungs expansion during breathing by achieving low friction, and it contains 
growth factors, cytokines and chemokines such as transforming growth factor ß (TGFß), 
platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast 
growth factor (FGF), IL1, IL15, IL16, IL18, etc. These components maintain the cellular 
integrity and help leukocyte infiltration in case of inflammatory response [12]. Pleural fluid is 
constantly secreted into the pleural cavity from the intercostal arteries and it is resorbed by 
lymphatic stomata on the parietal pleural surface [13]. In normal conditions the volume of 
pleural fluid does not exceed more than few milliliters (0.1–0.2 mL/kg), but in pathological 
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conditions of pleura it is dramatically increased, either due to increased production of pleural 
fluid and/or inhibited reabsorption. Increased formation of this fluid is either due to altered 
hydrostatic blood pressure or microvascular permeability, while infiltration of malignant cells 
may block the lymphatic drainage [14]. 
 
Figure 1. Oversimplified depiction of pleural cavity made from the space between 
mesothelial lining covering each lung. A) Healthy condition, B) Mesothelioma. 
Pleural effusions are often the results of circulatory congestion (transudate), or inflammatory 
lung disease (exudate). It could also be the result of metastases from other tumors such as 
metastatic adenocarcinomas from the lung (36%), breast (25%), malignant lymphomas (10%) 
and ovary and gastric adenocarcinoma (5%) [15]. Malignant pleural effusions can also be due 
to primary tumor of pleura which is MM, however with less frequent occurrence than 
secondary cancers. Since the subject of this thesis is MPM, the further focus will be on this 
kind of cancer. 
1.1.3 Diagnosis of malignant pleural mesothelioma 
MPM is one of the most aggressive malignant tumors with a long latency from asbestos 
exposure to disease manifestation. Patients have a short survival time between 9 to 12 months 
after diagnosis [4]. Diagnosis of mesothelioma is challenging particularly differentiating 
MPM from benign pleural effusions or other malignancies [16]. Disease symptoms have 
often slow onset and include dyspnea, weight loss, chest pain, cough, and accumulation of 
pleural fluid (effusions), which impede the breathing and is one of the most important 
symptoms. The diagnosis of pleural malignancies and the differentiation between metastatic 
pleural disease and MPM require morphological evaluations [17, 18]. 
1.1.3.1 Histology and Cytology 
Histologically there are three distinct phenotypes in MPM. One is known as epithelioid, in 
which cells show polygonal or cuboidal morphology. Epithelioid subtype is the most 
common type of mesothelioma (around 60% of all mesotheliomas). The second subtype is 
the sarcomatoid phenotype with fibroblast-like cells (around 10% of all mesothelioma), while 
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the third phenotype is biphasic with a mixture of both epithelioid and sarcomatoid cells 
(around 30%). The sarcomatoid phenotype has a worse prognosis than epithelioid phenotype, 
with higher rate of resistance to therapy [19-23]. The histological subtype of mesothelioma is 
associated with survival. The epithelioid phenotype is associated with longer survival 
compared with sarcomatoid and biphasic types [24]. This difference in therapy response and 
prognosis can be related to the differences in gene expression profile between the two 
phenotypes [25-27]. According to previous recommendations, diagnosis of MPM is based on 
histology [28], while recent recommendation from International Mesothelioma Interest Group 
is that cytological diagnosis of epithelioid mesothelioma is possible with advantages of using 
pleural effusions as less invasive method than biopsy and faster confirmation of diagnosis 
[16, 29]. One disadvantage of this method is that the sarcomatoid mesotheliomas will not be 
perceived as this phenotype usually does not shed malignant cells into the pleura. 
Histological diagnosis is based on the hematoxylin-eosin staining of tissues, also using a 
panel of immunohistochemical markers. Such a panel should contain positive markers for 
mesothelioma and excluding markers. The challenge in epithelioid morphology is to 
differentiate from metastatic adenocarcinomas as well as from reactive mesothelial 
proliferations. Recognition of the sarcomatoid or mixed phenotypes can be critical in clinical 
decision making. Differential diagnosis of sarcomatoid mesothelioma and other spindle cell 
neoplasm and also differential diagnosis of biphasic mesothelioma and other biphasic tumors 
such as synovial sarcoma are challenging [30].  
Cytological diagnosis can be performed based on the effusion that is obtained by 
thoracentesis to reduce patients’ symptoms by facilitating their breathing. The most important 
cytological features of MM include high cellularity, with numerous cell groups of varying 
size. The nuclear atypia may be substantial, but is often blend and difficult to distinguish 
from a reactive mesothelial condition. The cell groups may contain acidophilic extracellular 
matrix cores, and the cytological specimens sometimes show an acidophilic granular 
background, correlating to hyaluronan production of the tumor [29]. 
1.1.3.2 Adjuvant techniques 
The diagnosis will be performed using adjuvant techniques such as fluorescence in situ 
hybridization (FISH), immunocytochemistry or immunohistochemistry, electron microscopy 
and biomarkers.  
FISH can be used to demonstrate chromosomal abnormalities such as aneuploidy, which 
indicates malignancy [31]. Therefore, the main use of FISH analysis is to distinguish 
malignant from reactive cells. A commonly used commercial kit (Urovysion, Abbot) adopted 
also for pleural effusions uses three fluorescence probes to centromeric sequences on 
chromosomes 3, 7 and 17 showing chromosomal gains or losses and a fourth probe that labels 
the 9p21 band, containing the tumor suppressor cyclin-dependent kinase inhibitor gene p16, 
p16INK gene (CDKN2A). A homozygous deletion of the 9p21 band is a common finding in 
MM [31]. 
Immunocytochemistry is a well-established method to obtain diagnosis, however the 
challenge of determining reactive cells exists using this method. Although some reports 
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suggest that strong membranous staining with antibody against epithelial membrane antigen 
(EMA) from the E29 clone is a good marker for distinguishing mesothelioma from reactive 
mesothelial hyperplasia [32, 33]. Simultaneous desmin and calretinin positivity is also 
indicative for a reactive condition.  
Immunological markers of mesothelial lineage are calretinin, mesothelin, wilms tumor-1 
(WT1), HBME-1, CK 5/6, thrombomodulin and D2-40 (podoplanin). Calretinin, WT-1 and 
D2-40 have so far the greatest specificity for mesothelioma. In order to differentiate lung 
adenocarcinoma from mesothelioma, thyroid transcription factor-1 (TTF-1) and/or napsin A 
could be used [23]. In addition, estrogen receptor alpha (ER) and mammaglobin (MG) are 
good differentiating markers for breast adenocarcinoma from mesothelioma [34]. 
Electron microscopy is another useful tool in mesothelioma diagnosis. This method is 
especially useful when differentiating between mesothelioma and other metastatic 
malignancies. The ultra-structure of mesothelial cell include long thin microvilli on cell 
surface, abundant intermediate filaments, and prominent accumulations of intracytoplasmic 
glycogen and the formation of neolumina [35]. 
1.1.3.3 Soluble Biomarkers  
Biomarkers can be helpful in establishing the diagnosis earlier, assessing prognosis and 
predicting theraputical responses in patients. Yet, diagnostic, prognostic or predictive 
biomarkers are not widely established in clinical practice, although there are several 
mesothelioma biomarkers described. Depending on whether these biomarkers are measured 
in pleural effusions or serum, and on the analytical method used in the laboratories, 
biomarkers demonstrate varying specificities and sensitivities.  
Hyaluronic acid (HA) or hyaluronan is an extracellular polysaccharide in connective tissues. 
It has been reported that effusion levels of HA in MPM patients could be a diagnostic marker 
[36, 37], with sensitivity comparable to mesothelin [38], although with better performance in 
receiver operating characteristic (ROC) plot analysis. Moreover, a two-step model has been 
proposed with high specificity using hyaluronan and N-ERC/mesothelin in effusions to 
predict mesothelioma [39].  
To date, the cell surface glycoprotein mesothelin, when measured in serum or pleural 
effusion, is a good adjuvant diagnostic marker, although with less specificity than HA. The 
term soluble mesothelin related protein (SMRP) is given to isoforms of mesothelin which can 
be found in blood [40]. Several studies have shown that SMRP level in serum or pleural 
effusions of patients with advanced stage epithelioid and biphasic MPM was higher 
compared to early stage, and decreased SMRP level has been reported as an indicator of 
tumor shrinkage after therapy [34]. Data suggest that mesothelin could be used as a 
prognostic marker indicating poor survival [41-43]. 
Osteopontin (OPN) is highly phosphorylated matricellular protein involved in the formation 
of teeth and bone matrix and type I immune responses. OPN has been suggested as another 
marker for mesothelioma diagnosis with effective diagnostic accuracy in serum and plasma 
[44]. 
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MicroRNAs (miRNAs) are short (19-25 nucleotides) non-coding RNAs, which are involved 
in various cellular processes by affecting post-transcriptional regulation of genes. In MPM, as 
other tumors, microRNAs are dysregulated [45]. Several micoRNAs are identified so far in 
MM cell lines, tumors and patients’ blood, such as miR-29c*, by which increased expression 
predicted a more favorable prognosis [46]. In addition, in biological samples such as plasma, 
increased levels of miR-29c*, miR-92a and miR-625-3p are suggested as tumor markers for 
MM [47]. In general, miRNAs in the MM tumors and peripheral blood of patients seem to 
serve as potential biomarkers and/or therapeutic targets. 
1.1.4 Molecular pathogenesis of malignant mesothelioma 
The pathogenesis of MM is known to be multifactorial. Although around 90% of 
mesothelioma patients have been exposed to asbestos, other factors such as familial 
predispositions, radiotherapy, Simian virus 40 infection, and genetic and environmental 
factors potentiate the mesothelioma development which details are beyond the scope of this 
thesis.  
There are four proposed mechanisms by which asbestos is thought to damage pleura. First, 
making a physical damage by deep penetration of asbestos fibers when they are inhaled and 
irritating the pleura [48]. Second, asbestos fibers might interfere with the mitotic spindle of 
cells and consequently mitosis, which leads to aneuploidy and other chromosomal damage 
[49]. Third, asbestos produces iron-related reactive oxygen species which damage DNA [50]. 
Fourth, asbestos phosphorylates two kinases of mitogen-activated protein (MAP) kinases and 
extracellular signal–regulated kinases (ERK) 1 and 2. The higher activity of these kinases 
enhances the expression of early-response proto-oncogenes that encode members of the Fos–
Jun and activator protein 1 families [51, 52]. 
At the molecular level, growing evidence shows accumulation of a broad spectrum of genetic 
changes that lead to cancer. Some of the most common abnormalities are chromosomal loss 
of the short arm (p) of chromosomes 1, 3, and 9, and loss of the genetic material from the 
long arm (q) of chromosomes 6, 13, and 15. In addition anomaly in regulatory genes p16 and 
p14 which are expressed at the 9p21 locus (p16INK4a, p14ARF), chromosome 22 (NF2), and 
loss of 3p21 is the result of mutation of the BAP1 gene (BRCA 1-associated protein 1) [53]. 
The cyclin-dependent kinase inhibitor 2A (CDKN2A)/ alternative reading frame (ARF) gene 
is one of the most frequently inactivated tumor suppressor genes in MM. CDKN2A locus 
encodes p16INK4a, which inhibits the progression of G1 to S phase of cell cycle via the 
cyclin-dependent kinase 4/cyclin D- retinoblastoma protein [54]. ARF encodes p14ARF, 
which stabilizes p53 and retinoblastoma protein, thus causing G1 and G2 arrest in cell cycle 
[55, 56].  
NF2 encodes a protein called merlin with tumor suppressor properties. Merlin affects cell 
proliferation and growth via regulating the Hippo and mammalian target of rapamycin 
(mTOR) pathways [57].  
The importance of familial genetic susceptibility is pronounced in BAP1 mutation, where 
families with this mutation developed various kinds of cancer, including mesothelioma [58-
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60]. BAP1 encodes deubiquitinating enzymes which are involved in histone modification and 
therefore affecting global gene expression profiling, acting as tumor suppressors [61]. 
 
Figure 2. Summary of genes and proteins which are involved in MM development 
 
1.1.5 Role of intracellular signaling in malignant pleural mesothelioma 
The “molecular pathology” concept refers to signaling molecules and transcription factors 
from different pathways which are involved in tumor pathology. MPM exposure to asbestos 
fibers initiates multiple cell signaling pathway abnormalities, which consequently lead to 
cancer [53].  
Several enhanced receptor activations due to growth factor binding, or inactivating mutations 
in the NF2 gene cause activation of intracellular signal transduction pathways. Bodies of data 
demonstrate aberrant activation of phosphatidylinositol-3-kinase and protein kinase B 
(PI3K/AKT), ras/raf/MEK/MAPK pathways [53, 62], Hippo signaling cascade [63] and 
Hedgehog signaling [64]. These changes will ultimately lead to excessive proliferation, 
angiogenesis, invasion, metastasis, as well as resistance to therapy. 
Epidermal growth factor (EGF) and its receptor (EGFR) have been reported to be involved in 
mesothelioma development and progression by receptor auto-phosphorylation in mesothelial 
cells after asbestos exposure leading to MAPK cascade activation and inducing proto-
oncogenes c-fos and c-jun and initiating the carcinogenesis process [65].  
Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are 
two prominent angiogenic factors. It has been reported that high VEGF levels are observed in 
pleural effusions from mesothelioma patients compared to non-malignant group and there is 
inverse correlation between VEGF levels and mesothelioma patient’s survival [66]. High 
levels of bFGF in mesothelioma pleural effusion was found to be correlated to shorter 
survival, however the levels were lower in mesothelioma compared to non-malignant group 
[67]. 
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One of the important growth factors in mesothelioma is transforming growth factor-α (TGF-
α), which binds to EGFR with high affinity and it inserts its effects through activation of 
tyrosine kinase activity of this receptor [68]. Transforming growth factor β1 (TGF-β1) affects 
VEGF production and together they are involved in pleural effusion formation and 
mesothelioma cell growth [63, 69].  
Platelet-derived growth factor (PDGF) could have both autocrine/paracrine growth factor 
roles for mesothelioma cells. mRNAs from PDGF A- and B- chains are higher in 
mesothelioma compared to normal mesothelial cells [53, 70]. 
High levels of hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF), have 
been detected in pleural effusions of rats receiving asbestos intra-tracheally [71]. In 
mesothelioma patients, high levels of HGF in serum compared to healthy individuals [72] and 
immunoreactivity of tumor sections for HGF and its receptor Met have been demonstrated 
[73]. High signaling activities of AKT and ERK1/2 have been observed due to increased 
level of HGF that resulted in increased migration, cell division and invasiveness of 
mesothelioma cells [74]. 
1.1.6 Angiogenesis in malignant pleural mesothelioma 
During carcinogenesis, when tumor is less than 0.5 to 1 mm in diameter, there is a balance 
between pro- and anti-angiogenic factors. This results in the so called ‘’angiogenic switch’’ to 
be off. However, when this switch gets on and the balance favors pro-angiogenic factors, 
tumor starts to vascularize, and metastatic growth initiates [75].  
VEGF is the most prominent angiogenic factor with roles in vessel hyper-permeability and 
carcinogenesis. High expression of VEGF has been found in epithelioid and biphasic 
mesothelioma [53, 76]. Several studies show that vessel permeability and microvascular 
density positively correlate with VEGF levels in malignant pleural effusions. In addition, 
increased microvessel density is suggested to be independent predictor of poor prognosis in 
mesothelioma [77, 78]. Moreover, VEGF receptors (VEGFR-1, VEGFR-2 and VEGFR-3) 
are highly expressed in MPM [79, 80]. 
Bevacizumab is an antibody which neutralizes VEGF and has shown activity in various 
cancer types such as metastatic colorectal cancer, metastatic non-squamous non-small cell 
lung cancer and metastatic breast cancer. The use of bevacizumab in combination with 
pemetrexed plus cisplatin significantly increased survival in MPM with manageable side 
effects [81-83]. 
Since other tyrosin kinase receptors such as FGF, HGF and PDGF are also involved in 
mesothelioma pathogenesis (mentioned earlier in 1.1.5), multi-targeted tyrosine kinase 
inhibitors (TKIs), are other options for treatment, which are still evaluated in clinical trials. 
However, to date no significant positive results have been reported [81]. An example is using 
Axitinib (VEGF and PDGF receptors inhibitor) in combination with cisplatin and pemetrexed 
in MPM patients, where Axitinib could reduce angiogenesis; however, there was no positive 
clinical outcome [84]. 
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1.1.7 Treatment of malignant mesothelioma  
Mesothelioma is often resistant to chemotherapy. The standard treatment is cisplatin and 
pemetrexed combination which increases patient’s survival up to 2.8 months compared to 
single treatment with cisplatin [85]. On the other hand sarcomatoid and biphasic MPM 
demonstrate poor response to standard treatment and associate with worse prognoses [86]. 
Several other regimens have been studied as second-line therapy but results are not 
convincing yet. Since NF2 gene inactivation causes deregulation in intracellular signaling and 
affecting FAK, ERK, HER1 and 2 and mTOR pathways, an mTOR inhibitor, was tested in 
MPM and demonstrated median progression free survival of 2.8 months [87]. Several TKIs 
are in trials for MPM, such as sorafenib (TKI against VEGFR isoforms, PDGFR-α and β, 
EGFR), sunitinib (TKI against VEGFR, PDGFR, c-Kit), gefitinib and erlotinib (TKI against 
EGFR). No significant response is seen in MPM treatment using these agents yet [86]. 
Radiotherapy is mostly used to treat pain in MPM [88, 89]. Since mesothelioma is a diffuse 
disease often engaging large areas or the entire pleura, radiotherapy should be excessive and 
cover the whole hemithorax [90]. In a study of postoperative radiotherapy, there was no 
significant difference in median survival between those who received radiotherapy after 
surgery and chemotherapy and the group who did not receive radiotherapy [91].  
Surgery (pleuropneumonectomy) might be an option especially at early stages of disease 
when mesothelioma is still localized and metastasis has not occurred yet. However, 
guidelines are different in the world and surgery is not performed in all countries, including 
Sweden. Surgery could be performed either by removing the whole affected pleura and lungs 
and sometimes diaphragm (extrapleural pneumonectomy (EPP)), or less aggressively 
pleurectomy/decortication or resection (P/D) of tumor tissue in pleura, lung and chest wall 
[92, 93]. The mortality rate after EPP is relatively high, (32% in the past and recently with 
surgical techniques development is reduced to 4%). Mortality rate by P/D is 1.5-5.4%. In 
general, if disease is still progressive after chemotherapy, surgery is not recommended [89].  
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1.2 SYNDECAN-1 BIOLOGY 
1.2.1 Proteoglycans  
Proteoglycans (PGs) are abundant molecules on the cell surface, in the extracellular matrix 
and intracellular compartments. These molecules are composed of a core protein bearing 
covalently attached glycosaminoglycan (GAG) chains. Based on the disaccharide structures 
of GAG chains which will be explained later, there are six types of GAGs: the 
galactosaminoglycans chondroitin sulfate (CS), and dermatan sulfate (DS), the 
glucosaminoglycans heparan sulfate (HS), heparin, keratan sulfate (KS), and Hyaluronan 
(HA) [94, 95]. 
Except for hyaluronan (HA), which is freely present in the extracellular matrix, other GAG 
chains are parts of PGs [94, 96]. PGs serve their biological functions through both GAG 
chains and core proteins. These functions are through binding the positively charged effector 
proteins such as growth factors, cytokines and chemokines to GAG chains, or complex 
formations through the core protein with other proteins as integrins and modulating their 
intracellular signaling [97]. Therefore, these complex molecules are involved in wide range 
of cell processes from proliferation, angiogenesis, migration, adhesion and motility to 
apoptosis, both in physiological and pathological conditions such as organogenesis, and 
tumor progression. 
1.2.2 Syndecans 
There are two major cell surface PG families: syndecans, which are transmembrane PGs, and 
glypicans, which are covalently attached to the membrane by a glycophosphatidylinositol 
(GPI) lipid anchor [96]. The mammalian syndecans are a family of four members: syndecan-
1-4. Syndecan-1/CD138 is mostly expressed by epithelial cells and plasma cells, syndecan-
2/fibroglycan is found on mesenchymal cells, syndecan-3/N-syndecan is expressed on neural 
crest-derived cells and cartilage, while syndecan-4/amphiglycan is expressed ubiquitously, 
but at lower levels than other syndecans. [98]. However, expression of syndecan family 
members might be affected by other members due to compensatory mechanisms [99]. 
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1.2.3 Syndecans’ structure 
 
Figure 3. Syndecan-1 is a prototype in syndecan family. TM is transmembrane domain, C1 
and C2 are conserved regions 1 and 2, V is the variable region in syndecan family. Heparan 
sulfate (HS) and chondroitin sulfate (CS) chains are attached to the ectodomain. For heparan 
sulfate attachment, there are three highly conserved serine-glycine sites amino acids 37,45 
and 47 close to the N terminal of the core protein and chondroitin sulfates are attached to two 
highly conserved serine-glycine sites amino acids 210 and 220 [100].  
1.2.3.1 Core protein 
Syndecans are single passed type I transmembrane PGs, with a short C-terminus cytoplasmic 
domain, a transmembrane domain and an N-terminal ectodomain. The whole core protein has 
a molecular weight between 20-40 kDa. 
Within the cytoplasmic domain there are two conserved C1 and C2 regions which have 
flanked a region that varies between the four members of syndecan (V region). C1 region 
interacts with PDZ-containing intracellular proteins such as ezrin by which syndecan-2 can 
interact with actin [101]. This region is involved in endocytosis, exosome biogenesis, nuclear 
localization [102]. This domain also contains the consensus sequence: RMKKK, which has 
been shown to be nuclear localization signal for syndecan-1 [103]. The C2 region can interact 
with PDZ proteins such as syntenin, synectin and can also act as phosphorylation site. V 
region interacts with actin and fascin, and in this way, affect the cell spreading. In syndecan-2 
and -4 it has been shown that through V region, a ternary signaling complex with 
phosphatidylinositol 4,5-bisphosphate and protein kinase Cα is formed and leads to formation 
of microfilament bundles and focal adhesions [104-106] 
The transmembrane domain of syndecans contains GXXXG motif that is responsible for 
dimers formation. The biological consequence of this dimerization is still unknown, however 
GXXXG motif has been linked to stability and activation of signaling complexes in integrin 
and erbB receptors [106, 107].  Moreover, to what extent syndecans form hetero-dimers in 
the living cell is still unclear. Syndecans can dimerize with different affinities, for instance 
syndecan-1 transmembrane domain dimerizes weakly and the syndecan-2 transmembrane 
domain dimerizes very strongly [107]. 
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The ectodomain of syndecans varies among syndecans, however it has conserved sites for 
GAG chains attachment. Syndecan-1 has five attachment sites for GAG chains: three are 
close to the N-terminus and two are near the plasma membrane. These GAG chains are 
mainly HS chains attached to serine residues of a serine–glycine motif. In addition to HS 
chains, syndecan-1 and -3 may also have CS chains. HS can be found close to the N-
terminus, however CS chains are placed close to the cell membrane [102, 108]. 
Ectodomain is crucial in interacting with a wide range of ligands in extracellular matrix, such 
as growth factors, cytokines, chemokines, collagens and proteinases. These interactions are 
mediated through HS chains. The extracellular domain can get shed through the specific 
enzymes that cleave the protein core at specific locations, which will be discussed later. The 
shedding is constant, but it could increase in some pathological conditions such as 
inflammation, cancer progression, metastasis or wound healing [95]. The spatial location of 
HS chains close to N-terminus seems to facilitate these interactions with biological effectors. 
In addition, the presence of CS chain near the plasma membrane could affect syndecan-1 
clustering, association with other transmembrane receptors and change the susceptibility to 
cleavage proteases [102]. 
1.2.3.2 GAG chains 
Sulfated GAG chains are polymers composed of repeating disaccharides, which form long 
highly negatively charged polysaccharides. These disaccharides might be N-acetylated 
hexosamines (N-acetyl-D-galactosamine; GalNAc or N-acetyl-D-glucosamine; GlcNAc) 
bound to a D-/L-hexuronic acid (D-glucuronic acid; GlcUA or L-iduronic acid; IdoUA) or in 
one case D-galactose (Gal).  
The complex synthesis of the sulfated GAG chains occurs in the Golgi apparatus. Both HS 
and CS/DS chain synthesis initiate with the formation of a tetrasaccharide linkage to the 
hydroxyl group of serine residues on the ectodomain. This linkage consists of xylose–
galactose–galactose–glucuronic acid residues, which will be followed later by the repeating 
disaccharides. These disaccharides are glucuronic acid (GlcUA)–N-acetylglucosamine 
(GlcNAc) in HS or GlcUA–N-acetylgalactosamine (GalNAc) in CS chains which will be 
added to the linkage by EXTL 1-3 transferases. GlcUA residues on CS can then be 
epimerized into L-iduronic acid (IdoUA) which can transform this GAG to DS [109]. How 
exactly the balance between HS and CS/DS biosynthesis is regulated at this step, remains to 
be studied in vivo.  
The chain elongation termination mechanism is still not clear to date. Once the HS chain is 
around 50–150 disaccharides, these chains undergo several enzymatic modifications. These 
modifications include deacetylations, sulfations and epimerization. Chain modifications do 
not occur uniformly and not on all the synthesized chains, so some parts of HS chains for 
instance can be more sulfated than other parts. These result in highly diverse chains at the end 
of process [108, 110]. 
In HS the first modification enzyme is the N-deacetylase/N-sulfotransferase (NDST1-2) that 
replaces N-acetyl group of GlcNAc with a sulfate group resulting in N-sulfoglucosamin 
(GlcNS). Then the next modification is C5-epimerization of GlcUA residues adjacent to 
GlcNS residues to IdoUA units.  
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These modified disaccharides will then undergo a series of O-sulfations. An iduronosyl 2-O-
sulfotransferase (2-OST), followed by a glucosaminyl 6-O-sulfotransferase (6-OST1-3), and 
glucosaminyl 3-O-sulfotransferase (3-OST1-7) will modify the chains. The source of sulfate 
for these reactions is 3′-phosphoadenosine 5′-phosphosulfate (PAPS) which is synthesized 
from ATP and SO3. There are multiple isoforms for sulfotransferases, which some are tissue 
specific and could have different substrate specificities. For instance, although 6-O-
sulfotranferases can act on both GlcNAc and GlcNS [111], it has been reported that 6-O 
sulfation preferentially occurs on GlcNS which is flanked by 2-O-sulfated IdoA [112]. The 
biosynthesis machinery leads to extensive polysaccharide structural heterogeneity, providing 
highly specific binding sites for protein ligands. Moreover, HS chains vary among different 
cell types and tissues, which might explain the regulation of different biological functions 
[110]. In CS/DS, the chain modification is driven through variable O-sulfations of any free 
OH group. Thus GalNAc-4, -6, GLcUA-2, or -3 and also IdoUA-2 in DS can be sulfated 
[109, 113].  
After HS chain gets synthesized, there are several mechanisms by which HS chains can be 
modulated on the cell surface, resulting in even more diversity of chains. One modification is 
removal of 6-O-sulfate groups from HS on the cell surface. This process is mediated through 
two endosulfatases SULF1-2 which are secreted to the extracellular space [114]. Another 
mechanism is by truncation of the whole core protein of the proteoglycan which is known as 
shedding. Syndecans are for instance shed by matrix metalloproteinases [115]. Moreover, 
heparanase in the extracellular matrix trims HS, which leads to shorter but potentially more 
bioactive HS fragments [116]. 
A study show that HS chains on syndecan-1 and -4 from the same cell type are the same 
[117], however HS chains from the same core protein on different cells are different [118, 
119]. On the other hand, CS chains on syndecan-1 are different from CS chains attached to 
syndecan-4 in mammary gland cells, while again HS chains from these two core proteins 
from the same source are the same [120].  
1.2.4 Ectodomain shedding of syndecans 
Ectodomain shedding of PGs is an important posttranslational modification that regulates 
pathophysiological processes. All membrane-bound proteoglycans shed regardless of which 
proteoglycan is expressed in the specific cell. When the truncated part of proteoglycan is 
released, the amount of cell bound GAG chain decreases, while the extracellular soluble 
ectodomain can still act as autocrine or paracrine receptor, competitively binding the same 
ligand as the membrane bound form, and thereby influencing the cell behavior. Syndecan 
ectodomain undergo proteolytic cleavage caused by groups of enzymes which are referred as 
sheddases. Shedding is highly regulated and occurs in all mammalian syndecans which bear 
specific cleavage sites close to cell membrane [95, 121].  
The matrix metalloproteinases (MMPs) are syndecan sheddases with broad substrate 
specificity. Therefore, they are involved in many physiological processes such as 
development and reproduction and matrix remodeling, and also in pathological conditions as 
inflammatory disease and cancer progression and invasion. MMPs usually cleave before 
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hydrophobic residues as Leu, Ile, Met, Phe or Tyr, while cleavage before a charged residue is 
rarely seen [122].  
Matrilysin (MMP-7) [123] and membrane-associated metalloproteinases MT1-MMP and 
MT3-MMP can cleave syndecan-1 [124]. MMP-2 and MMP-9 can cleave syndecans-1, -2 
and -4 [125, 126]. The precise cleavage site can vary, depending on the proteases. These 
proteolyses take place on amino acids clusters located 6–15 residues from the plasma 
membrane. MT1-MMP cleavage site on human syndecan-1 is at Gly245–Leu246 [124, 127]. 
Human syndecan-4 is shed at Lys114–Arg115/Lys192–Val130 and Lys114–Arg115, through 
serine proteases plasmin and thrombin, respectively [128]. 
Syndecan-1 shedding is enhanced in physiological and pathological conditions, such as 
physiological response to growth factors [129], chemokines [130], cellular stress [115], 
wound healing [131]. Likewise enhanced shedding is seen in sepsis [132], multiple myeloma 
[133], lung cancer [134] and Hodgkin’s lymphoma. Shedding can also be experimentally 
increased due to trypsin [135], and heparanase [136]. 
The cleaved syndecan ectodomain can accumulate in the physiological compartments, for 
example syndecan-1 accumulation in skin [137] during wound healing and in serum of cancer 
patients.  
It has been shown that GAG chains play important roles in modulating the shedding. A 
reduction of GAG content on syndecan-1 by recombinant human heparanase or bacterial 
heparinase III increased syndecan-1 shedding [138, 139]. There are several proposed 
mechanisms for this: 1) HS chains physically block the access of sheddases to their cleavage 
sites, 2) core protein containing HS chains is more stable in a conformation with less 
susceptibility to proteolysis, 3) HS chains maintain the syndecan- Rab5 complex [136]. Rab-5 
is a small GTPase regulating intracellular trafficking and signaling pathways which is bound 
to syndecan-1 cytoplasmic domain and can initiate syndecan-1 shedding [140]. 
1.2.5 Syndecan-1, prototype member of the syndecan family 
During embryogenesis syndecan-1 is expressed during epithelial-mesenchymal transitions by 
mesenchymal cells. Later syndecan-1 expression will be limited to epithelial cells, pre-B cells 
and plasma cells [141].  
Syndecan-1 is mainly expressed on the basolateral surface of epithelial cells [142], and bind 
to extracellular matrix (ECM) components, such as fibronectin [143], collagens I, III and V 
[144], and thrombospondin [145]. Moreover, the intracellular domain acts as an anchor and 
connects to actin cytoskeleton [142]. Therefore, this HSPG received the name ‘syndecan’ 
from the Greek word: syndein, which means to bind together, as is able to stabilize the 
epithelial sheets via connecting the ECM to the intracellular cytoskeleton. 
As other members of syndecan family, syndecan-1 can regulate a wide variety of biological 
activities through HS chains binding to a wide range of bioactive effectors such as vascular 
endothelial growth factors (VEGFs), transforming growth factor-β (TGF-β), fibroblast 
growth factors (FGFs), hepatocyte growth factor (HGF), platelet-derived growth factors 
(PDGFs), and cytokines. These interactions influence the biological functions including 
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developmental processes, proliferation, apoptosis, wound healing, migration, angiogenesis, 
blood coagulation, tumor metastasis, infection, and inflammation. All these roles are crucial 
in development and progression of cancer [98]. 
Depending on the cell type, the fine structure of GAGs on syndecans can be different. This 
leads to various ligand affinities, function and activity of syndecan-1 among tissues. For 
example, syndecan-1 on simple epithelial cells carry more and larger HS and CS chains than 
syndecan-1 on stratified epithelial cells [146]. In addition, syndecan-1 from NIH-3T3 cells 
can bind laminin [147], whereas syndecan-1 from a mammary epithelial cell line cannot 
[148].  
Interestingly, mice lacking syndecan-1 are fertile and healthy. However, when these mice 
were challenged with disease-causing agents or conditions, dramatic pathological phenotypes 
emerged [149]. This suggests that there is a compensatory mechanism by other syndecans or 
HSPGs which can be functional even when syndecan-1 is lost during normal development, 
but this mechanism is not efficient in certain post-developmental processes, such as the 
pathogenesis of diseases. This implies a crucial role for pathogenic involvement of syndecan-
1 [98]. 
1.2.6 Syndecan-1 in cancer 
The epithelial-mesenchymal transition (EMT) occurs during cancer progression. During 
this process epithelial cells gain mesenchymal cells characteristics, whereby they become 
more mobile resulting in invasion and metastasis [150]. Transforming growth factor-beta 
(TGF-β) is shown to be involved with activation of EMT inducing transcription factors 
[151]. This change is reversible and when cells are settled down to form a metastasis, cells 
can return to their original epithelial phenotype, this process is named mesenchymal-
epithelial transition (MET) [152]. Epithelial cells have adherent junctions and tight cell-cell 
interactions which are mainly mediated through E-cadherin from one cell adhering to the 
neighboring cells. The cytoplasmic end of this protein chain is associated with actin 
filaments [153]. During EMT syndecan-1 and E-cadherin are both lost. Depletion of these 
two alters morphology and anchorage-dependent growth, causing enhancement of cellular 
motility [154, 155]. Therefore, syndecan-1 presence is necessary to maintain the epithelial 
morphology.  
As other proteoglycans, syndecan-1 has important roles in tumor biology through altering key 
processes of tumorigenesis, such as cell proliferation, angiogenesis, apoptosis, etc. [156]. The 
expression of syndecan-1 is dysregulated in different cancer types such as mesothelioma 
[157, 158] and carcinomas of the lung [159], prostate [160], pancreas [161], breast [162], 
ovary [163] and colon [164] and multiple myeloma . However, it is noteworthy that 
depending on the cancer type, the levels of surface or soluble (shed) syndecan-1 might 
influence the prognosis. For example, in head and neck [165], lung [159] and colorectal [166] 
cancers, low syndecan-1 expression in tissue is associated with worse prognosis, while high 
levels of shed syndecan-1 in serum correlate with a poor prognosis in lung cancer [134] and 
myeloma [133].  
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Table 1. Adapted from Szatmári T. et al. 2015 [167]. + demonstrates good prognosis, - stands 
for poor prognosis and ± shows conflicting data. 
Cancer type  Stromal 
syndecan-1 
Cell surface 
syndecan-1 
Soluble 
syndecan-1 
 
Intrathoracic 
cancers 
Mesothelioma  + - 
Lung  + - 
 
Skin cancers 
Basal cell 
carcinoma 
 +  
Squamous cell 
carcinoma 
+ +  
 
 
Head and neck 
cancers 
Head and neck - +  
Laryngeal, 
hypopharynx 
  - 
Nasopharyngeal  -  
 
 
 
Gastrointestinal 
cancers 
Gastric - +  
Colorectal - ±  
Hepatocellular  +  
Pancreatic  -  
Breast cancer Breast cancer ± ± - 
 
 
 
 
 
Urogenital 
cancers 
Cervical  +  
Ovarian - -  
Endometrial - ±  
Prostate - ±  
Bladder - + - 
Urothelial -   
 
Hematological 
malignancies 
Myeloma  - - 
Hodgkin’s 
lymphoma 
 -  
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1.2.6.1 Syndecan-1 roles in proliferation and apoptosis 
Syndecan-1 regulates tumor cell proliferation and survival through different mechanisms 
which could be tissue type dependent. Several signaling pathways have been associated with 
the role of syndecan-1 as a co-receptor.  Syndecan-1 acts in an HS-dependent fashion as a co-
receptor for Wnt signaling and syndecan-1 null mice were resistant against Wnt-1 induced 
mammary tumorigenesis [168]. 
Hepatocyte growth factor (HGF) signaling is conducted through its receptor, Met, which is 
important in cancer progression [169, 170]. In myeloma, HGF can bind HS chains of 
syndecan-1 [171]. This interaction enhances Met signaling and further PI3 kinase-protein 
kinase B and Ras-MAP kinase pathways activation [172]. Furthermore, in myeloma cells 
heparanase induces syndecan-1 shedding via MMP-9 upregulation [173] and also it increases 
HGF expression [174]. Shed syndecan-1 also augments this effect with binding to HGF and 
presenting it to osteoblasts. This results in inhibition of bone formation and promotion of 
bone resorption [175].  
In many tumor types, the role of shed syndecan-1 in the stroma depends on the cell type and 
might conflict the role of cell bound-syndecan-1. Stromal syndecan-1 enhances proliferation 
of breast epithelial cell [176], and in ovarian [163], oral [177] and gastric carcinomas [178], it 
is correlated to poor outcome.  On the other hand, the stromal immunoreactivity to syndecan-
1 in basal cell carcinoma is negatively correlated to aggressiveness [179].  
In tumor stroma, syndecan-1 shedding delivers growth factors to tumor cells and help to 
maintain the growth and survival of tumor cells. This is supported by data showing that 
ectodomain shedding of syndecan-1 from stromal fibroblasts stimulated tumor cell growth 
through the activation of FGF2 signaling [180]. Also, syndecan-1 overexpression in 
fibroblasts enhances cancer cell proliferation in mammary tumor cells [181]. Taken together, 
stromal syndecan-1 could store and present heparin-binding growth factors such as FGFs, 
HGF, and EGFs to cancer cells and enhance their proliferation [98].  
Syndecan-1 could also regulate tumor cell apoptosis in dual fashion in different cell types. 
For instance, in myeloma cells syndecan-1 silencing induced apoptosis [182], which might be 
explained by reduced levels of cell surface syndecan-1 as co-receptors for growth factor 
signaling. However, the opposite effect has been observed in MCF-7 breast cancer cells, 
where the addition of human recombinant syndecan-1 ectodomain increased apoptosis [183].  
It is not clear yet how exactly the cell surface and shed syndecan-1 can modulate growth and 
apoptosis in various cancer cells. As tumor cells can vary in terms of their requirements for 
growth factors, this might partly explain the differences among tissues. In addition, tumor 
microenvironment is unique for each tumor, and syndecan-1 HS chains could be different to 
either enhance or inhibit tumor cell growth or apoptosis [184]. 
Furthermore, HS chains play important roles as being inhibitory or stimulatory factors for a 
ligand activity. The activity curve for HS chains binding to their ligands might be bell-
shaped, meaning that at either sides of the optimal HS concentration, ligand activity could be 
low or high, which could explain the opposing roles of syndecan-1 in tumor cell proliferation 
and apoptosis [98].  
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1.2.6.2 The role of syndecan-1 in angiogenesis 
Syndecan-1 is able to bind to pro-angiogenic factors as VEGF and FGF-2 and presents them 
to their corresponding receptors on endothelial cells and enhance endothelial cells growth and 
sprouting. Shed syndecan-1 plays important role here in tumor angiogenesis and metastasis 
by increasing the local concentration of angiogenic factors to promote angiogenesis [98].  
In myeloma, heparanase mediated shedding of syndecan-1 promoted angiogenesis [185]. In 
addition, heparanase upregulated VEGF and HGF in myeloma cells, increasing their 
presentation through shed syndecan-1 to endothelial cells [173, 185]. It has been shown that 
heparanase promotes angiogenesis through generation of HS chains [186]. However, intact 
syndecan-1 ectodomain is also crucial for angiogenesis, as addition of intact syndecan-1 
ectodomain to rat aortas promoted angiogenesis [187]. 
Syndecan-1 ectodomain can bind to αvβ3 and αvβ5 integrins and form a ternary complex with 
insulin-like growth factor-1 receptor. This complex activates integrins, which are necessary 
for pro-angiogenic functions. The short synthetic peptide that mimics this integrin attachment 
sequence on syndecan-1 ectodomain (synstatin) inhibits syndecan-1 interactions with 
integrins and forming the ternary complex, and in myeloma blocks endothelial cell invasion 
and tumor growth in vivo [185, 188-190].  
Syndecan-1 expression in stromal fibroblasts is increased in several carcinomas, such as 
breast cancer [181], where it correlated with larger vessel areas and high microvessel density 
(MVD) [187]. 
1.2.6.3 The role of syndecan-1 in migration, wound healing and metastasis 
Membrane-bound syndecan-1 acts as adhesion molecule and increases cell adhesion to ECM, 
and hampers cell migration. This has been seen in squamous cell carcinoma cells where cell 
surface syndecan-1 loss reduced cell adhesion to collagen, but promoted cell migration and 
invasion [191].  
Integrins are important receptors in cell adhesion and migration. Syndecan-1 can interact with 
αvβ3 and αvβ5 integrins and activate their signaling via the engagement of αv ligands such as 
fibronectin (FN), laminins, vitronectin (VN), thrombospondin, and collagens [188]. In 
addition, syndecan-1 and integrins can link ECM to cytoskeleton and stabilize the focal 
adhesions, which causes limited cell migration and more adhesion [98].  
Furthermore, data suggest that membrane-bound syndecan-1 and shed syndecan-1 may play 
different roles at different stages of cancer progression. In MCF-7 breast cancer cells, cell 
surface syndecan-1 inhibited the invasion, while shed syndecan-1 promoted invasion of cells 
into Matrigel [192]. Likewise, cell surface syndecan-1 hampered migration of fibrosarcoma 
cells, where syndecan-1 ectodomains stimulated cell migration [124]. MMP inhibitors 
increased syndecan-1 expression on the cell surface and actin stress fibers were formed and 
caused cell migration inhibition [124].  
During wound healing, expression of MMPs and heparanase and consequently bioactive shed 
syndecan-1 are increased. Syndecan-1 null mice are viable, but show retarded wound healing 
in both skin and cornea, due to slow keratinocyte migration. It has been proposed that the 
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wound healing role of syndecan-1 is conducted by promoting cell migration, generating 
chemokine gradients, and modifying cell signaling [102, 124, 193]. 
Taken together, data suggest that loss of cell surface syndecan-1, which is seen in many types 
of carcinoma could reduce cell adhesion and enhance a more migratory and invasive capacity 
in cancer cells. 
1.2.6.4 Syndecan-1 in mesothelioma 
Cell surface syndecan-1 has been reported to be essential for maintaining normal epithelial 
cell morphology and anchorage-dependent growth, as loss of this PG on epithelial cells leads 
to anchorage independent growth, and cells can invade and migrate through collagen gels, as 
mesenchymal cells do [154]. In addition, reduced syndecan-1 expression has been correlated 
to less differentiation and malignant transformation of cells [194].  
Generally, cell-bound expression of syndecan-1 in mesothelioma is relatively lower than 
epithelial malignancies. In MM, expression of syndecan-1 could be used as a differentiation 
marker, therefore associating with better prognosis. Epithelioid subtype expresses higher 
levels of syndecan-1, while sarcomatoid subtype which is less differentiated demonstrates 
low or negative syndecan-1 expression [157, 195].  
Syndecan-1 overexpression on mesothelioma cells hampers tumor growth [99] and 
migration, while enhances cell adhesion [196]. These functional changes are along with 
morphological changes towards epithelioid direction [99], however syndecan-1 
downregulation leads to sarcomatoid phenotype, another indication of EMT transition and 
worse prognosis when syndecan-1 is less on these cells [195]. 
MM cells also express syndecan-2 and -4, which are less expressed in carcinomas [195]. 
Therefore, the ratio of syndecan-1 to -2 has been proposed as differentiating biomarkers of 
MM from metastatic adenocarcinoma [197, 198]. 
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2 AIMS 
 
The general aim of this thesis is to investigate the relation between molecular structure and 
function of syndecan-1 in MPM. This knowledge could be helpful in facilitating early 
diagnosis by using syndecan-1 as diagnostic or prognostic factor and understanding 
modulations of various cellular signaling pathways by this potential biomarker. 
Specific aims 
Paper I: To identify genes and pathways affected by syndecan-1 in mesothelioma 
Paper II: To assess the diagnostic and prognostic value of soluble syndecan-1 in pleural 
malignancies 
Paper III: To investigate syndecan-1 impact on heparan sulfate structure and sulfation    
pattern of proteoglycans in mesothelioma  
Paper IV: To explore the role of syndecan-1 in angiogenesis of mesothelioma 
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3 REMARKS ON METHODOLOGY 
3.1 CELL LINES 
Cell lines that were used in this thesis included MPM cell line STAV-AB (papers I, III and 
IV) and human umbilical vein endothelial cells (HUVECs; paper IV). The STAV-AB cell 
line, once established from a pleural effusion, grows with epithelioid phenotype and has low 
endogenous expression of syndecan-1 [195]. The STAV-AB cells were also transfected with 
a vector containing the human full-length syndecan-1 gene [99]. The level of syndecan-1 
overexpression was constantly ensured before experiments using fluorescence activated cell 
sorting. Human umbilical vein endothelial cells (HUVECs) were purchased from ATCC. 
3.2 PATIENT MATERIALS 
Pleural effusions and/or serum samples from patients (paper II, III and IV) had been collected 
at the Department of Pathology and Cytology, Karolinska University Hospital in Huddinge, 
Sweden and at the Medical Faculty of Eskisehir, Department of Chest Diseases, Turkey. All 
samples were from chemotherapy-naïve patients. Biomarkers synthesized in the pleura are 
less affected by biological elimination in the restricted pleural cavity compared to when they 
have entered the circulation. Measurements are thus more sensitive when performed on 
pleural effusions compared to serum. 
3.3 IMMUNE BASED ASSAYS 
3.3.1 Enzyme linked immuno-sorbent assay (ELISA) 
Sandwich ELISA was used in papers II, III, and IV to measure shed syndecan-1, VEGF and 
sulfatase-1 levels, using commercial kits. This technique is rather sensitive and provides 
semi-high throughput methods to measure specific antigens. 
3.3.2 Proteome Profiler Array 
This method was used in papers I, III, and IV. In paper I, expression of several proteins was 
measured to validate microarray results. In paper III receptor tyrosin kinase activity, and in 
paper IV angiogenesis related proteins were measured. Performing multiplex antibody array 
to detect multiple antigens is cost and time-effective. However, the chemiluminescence used 
in these assays, caused high inter-experimental variability in signal intensity causing higher 
standard deviations that could influence the detection of more delicate changes. 
3.3.3 Fluorescence Activated Cell Sorting (FACS) 
This method was generally used to validate syndecan-1 overexpression (paper I, III and IV) 
and to measure apoptosis (paper I), cell cycle (paper I and III) and the expression of variously 
sulfated regions of HS and different components of intracellular pathways (paper III). The 
technique allows the characterization of multiple parameters of single cells, physical 
properties such as size and granularity together with specific fluorescent antibody labels.  
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3.3.4 Immunocytochemistry 
Cell-bound syndecan-1 (paper II), and expression of ERK1/2 and pERK1/2 (paper III) were 
measured using fluorescent immunocytochemistry, which allows the binding of antibody to 
the antigen. The evaluation necessitates the use of positive and negative controls. 
3.4 TRANSCRIPTOMICS AND QUANTITATIVE PCR 
Microarray analysis on syndecan-1 overexpressing and silenced cells was used to identify 
their global gene expression (paper I and III), using Affymetrix GeneChip® Human Gene 1.0 
ST microarray. Gene ontology (GO) annotations were used to correlate genes with biological 
functions.  
Differentially expressed genes (DE) in the experiment are called altered gene sets (AGS) and 
genes that were previously known from the literature to be related to a function are called 
functional gene sets (FGS). To define the transcription profiles of affected genes three 
different approaches were used. First, based on Gene Ontology (GO), gene set enrichment 
analysis (GSEA) was used, which is a method using the maximum overlap of specific 
function between AGS and FGS. This analysis, considers DE genes that are linked to any 
FGS disregarding any known functional links within the analyzed AGS. 
Moreover, two different methods of gene network analysis were applied: ingenuity pathway 
analysis (IPA) and a novel method of network enrichment analysis (NEA). IPA performs 
GSEA on network modules of DE genes. IPA finds associations between AGS and known 
pathways or FGS, but this analysis considers the networks. Networks are modules of genes 
which are tightly connected. Thus, IPA considers only those DE genes that can be grouped in 
a network, by which errors might occur. 
The other network-based method was network enrichment analysis (NEA) that finds network 
connectivity between AGS and FGS. This method is a combination of conventional GSEA 
and IPA considering the links between genes of AGS and FGS in the global network. NEA 
finds over/under-representation of the neighboring FGS in the gene network rather than in the 
AGS. NEA has a higher statistical power than GSEA, since the potential connections 
between gene groups are expanded from listed genes to their network neighbors [199]. All 
the three methods of GSEA, IPA and NEA use known links from literature searches, 
therefore there is always the literature bias existing and the yet unpublished possible 
interactions are not taken into consideration.  
Sets of DE genes obtained from microarray were validated on mRNA level using quantitative  
real time polymerase chain reaction (qRT-PCR), which was performed with Platinum 
SybrGreen qPCR SuperMix-UDG kit. The quantity of DE genes was normalized to GAPDH 
as reference gene and to the corresponding controls. 
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3.5 ROC PLOT ANALYSES 
The performance of syndecan-1 as a diagnostic marker for malignancy was evaluated by 
receiver operating characteristic plot (ROC plot). This test plots the true positive rate 
(sensitivity) versus the false positive rate (1-specificity) at varying cut-off values and the 
usefulness of the marker analysis is reflected by the area under curve (AUC). An AUC value 
of 1.0 indicates a perfect test (100% sensitivity and 100% specificity) while AUC of 0.5 
indicates no diagnostic utility 
3.6 GENE SILENCING 
Transient silencing of syndecan-1 (paper I) and MMP-7 (paper IV) were performed using 
siRNA constructs for the corresponding gene. Scrambled siRNA sequences were used as 
negative controls. Silencing was validated on mRNA and/or protein level using qPCR and/or 
FACS. The advantage of siRNA silencing is that the effect is obtained in a few days.  
3.7 ANALYSIS OF HS SULFATION PATTERNS 
The fine structure of HS chains was studied by High Performance Liquid Chromatography 
(HPLC) as the composition of disaccharides obtained by heparinase digestion (paper III). 
Based on differences in binding constants to a cation, the variously sulfated compounds could 
be separated under reversed phase conditions (ion pair reversed phase). Obtained results were 
also verified by High Performance Capillary Electrophoresis (HPCE), using a silica capillary 
and reversed polarity. The latter needs considerably less material, but also requires further 
purification of the sample to be analyzed. The two methods verified each other, although 
HPLC gives more detailed information of less abundant sulfation pattern.     
3.8 FUNCTIONAL ASSAYS 
3.8.1 Proliferation assay 
The effect of syndecan-1 silencing on the proliferation of mesothelioma cells (paper I) and 
the effect of conditioned media from syndecan-1 overexpressing cells on HUVEC cell 
proliferation (paper IV) were evaluated using the WST-1 assay. The assay is a quantification 
of mitochondrial activity and reflects the number of viable cells present. A factor to consider 
is that any change in metabolic activity due to treatments also may affect the results. 
3.8.2 Cell cycle distribution  
The cell cycle distribution of mesothelioma cells was studied by flow cytometry following 
permeabilization of cell membranes by ethanol fixation and propidium iodide (PI) staining. 
The analysis defines the cell cycle progressions from G0/G1, G2/M and S-phase. The effect 
of syndecan-1 silencing (paper I), of syndecan-1 overexpression (paper III) and of exposure 
of these cells to sulfatase-1 (paper III) was monitored in this way. 
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3.8.3 Apoptosis assay 
The effect of syndecan-1 silencing on apoptosis was assessed using PI and FITC conjugated 
Annexin-V (paper I). During early apoptosis the cell membrane flips, exposing 
phosphatidylserine on the outside of the membrane, allowing the Annexin-V to bind. As the 
apoptosis progresses the cell membrane degrades, allowing PI to enter the cells, where it 
intercalates with the nuclear DNA. This progression is different from necrosis, where the cell 
membranes deteriorate, leaving PI labelled nuclei with no measurable increase in Annexin-V 
staining.  
3.8.4 Chemtoaxis assay 
The effect of conditioned media from syndecan-1 overexpressing cells on HUVEC cell 
chemotactic migration was measured using Transwell plates (paper IV). This method 
evaluates directional cell migratory capacity. HUVEC cells were seeded in the upper 
chamber and allowed to migrate downward through porous membrane towards the 
conditioned media. Percentage of covered area by migrated cells was measured with image 
processing software after membranes were stained with crystal violet.  
3.8.5 Wound healing assay 
The effect of conditioned media from syndecan-1 overexpressing cells on HUVEC cells 
migration was also measured using the Cytoselect wound healing assay (paper IV). HUVEC 
cells were seeded confluently and the wound was made using inserts in the wells. The cells 
were treated with conditioned media from syndecan-1 overexpressing cells, measuring the 
ability of HUVEC cells to close the wound area with image processing software. This method 
measures not only cell migration but also cell proliferation.  
3.8.6 Tube formation assay 
To investigate the ability of tubulogenesis of HUVEC cells due to conditioned media from 
syndecan-1 overexpressing cells, tube formation assay was used (paper IV). The HUVEC 
cells were seeded on extracellular matrix gel and incubated with conditioned media from 
syndecan-1 overexpressing cells. The features of tube formation were measured using image 
processing software. For reproducibility purposes care must be taken that the experiments are 
made with the commercial support matrices from the same batch.  
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4 RESULTS AND DISCUSSION 
4.1 PAPER I: Novel genes and pathways modulated by syndecan-1: 
implications for the proliferation and cell-cycle regulation of malignant 
mesothelioma cells 
Previous studies show that overexpression of syndecan-1 in MM inhibits tumor growth [99] 
and migration [196], along with epithelioid differentiation [99]. We also know that syndecan-
1 presence on mesothelioma cells correlates with better prognosis [157]. Therefore, in this 
paper we mapped the molecular changes related to syndecan-1 overexpression and silencing 
on the genes and pathways regulated by this heparan sulfate proteoglycan in a MPM cell line. 
To perform this, microarray analyses were used following syndecan-1 overexpression and 
silencing on MM cells with combining three different bioinformatics approaches of GSEA, 
IPA and NEA. Transcriptomic data were validated using real time-PCR and/or proteome 
profiler array. Moreover, functional assays on cell proliferation, cell cycle and apoptosis were 
performed after syndecan-1 silencing. 
Following syndecan-1 modulation either with overexpression or silencing, transcriptomic 
analysis demonstrated a remarkable effect on the global gene expression profile. Using a 
threshold of one and a half times up- or downregulation compared to controls, the number of 
differentially expressed genes (DE genes), were 2,389 and 103, after overexpression and 
silencing respectively. There were fourteen genes in common, which were affected by both 
overexpression and silencing of syndecan-1 (Table 1 in paper I).  The lower number of DE 
genes by syndecan-1 silencing could be explained by the initially low levels of endogenous 
syndecan-1 in MPM cells, which makes the silencing less pronounced. 
Functional characterization of DE genes regulated by syndecan-1 overexpression showed that 
these genes were involved in cell adhesion, proliferation, cell cycle progression, cell motility 
and migration, angiogenesis and ECM organization (Figure 4 in paper I). Furthermore, 
expression of cytokines (Table S4 in paper I) and TGFβ family members and their receptors 
and growth factors and their receptors including EGF, VEGF, PDGF and FGF were affected 
in syndecan-1 overexpressing cells. Since one mesothelioma cell line was used, cell line 
specificity of the obtained results cannot be ruled out. Downstream MAPK, JAK-STAT and 
TGFβ signaling pathway members were also modulated. The highly affected genes and 
signaling pathways affected by syndecan-1 overexpression based on KEGG pathways 
(depicted by Figure 5 in paper I), showed that the outcome of these alteration affects cell 
proliferation, differentiation and cell cycle.  
NEA analysis of syndecan-1 overexpressing and silenced cells revealed that all the analysed 
cell cycle pathways were enriched after syndecan-1 was silenced and nearly all of them were 
depleted after syndecan-1 was overexpressed. This highlights the role of syndecan-1 on cell 
proliferation (Figure 9B in paper I).  
Functional assays revealed that syndecan-1 silencing hampers cell proliferation, a finding 
which was seen before for syndecan-1 overexpression. However, cell cycle distribution 
showed a different mechanism for the two settings: due to syndecan-1 silencing cells were 
mostly accumulated in G0/G1 phase and less cells were in G2/M, while the effect of 
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syndecan-1 overexpression was more a prolonged S phase [99]. Apoptosis was not affected 
by syndecan-1 silencing. We hypothesized that the effect of syndecan might have a bell-
shaped curve, meaning that in order to have maximum cell proliferation an optimal level of 
syndecan-1 is needed. Below or above this level of syndecan-1, cell proliferation is inhibited. 
The mechanistic effect of syndecan-1 overexpression on proliferation could partly be 
explained by the findings that TGFβ2 was downregulated. In tumorogenesis TGFβ may act 
more as tumor promoter, as in mesothelioma the reduction of TGFβ inhibits tumor growth 
[200]. On the other hand sulfatase-1 was down regulated upon syndecan-1 overexpression. 
This can be debating as sulfatase-1 decreases the growth factor binding affinity of heparan 
sulfate proteoglycans with removal of 6-O-sulfation of heparan sulfate chains [118]. The 
change in sulfatase-1 was together with other enzymes involved in heparan sulfate sulfation 
patterning (SULT1B1 and SULT1E1), which were significantly downregulated upon 
syndecan-1 overexpression. All these disclose a possibility of GAG change and consequently 
growth factor binding and intracellular signaling modifications in these cells. 
Altogether, the data in paper I indicate that syndecan-1 regulates high number of genes and 
pathways profoundly affecting cell proliferation in mesothelioma cells. 
4.2 PAPER II: Diagnostic and prognostic value of soluble syndecan-1 in 
pleural malignancies 
Pleural effusion is usually the first available diagnostic material in pleural malignancies. 
However, differentiation between benign and malignant pleural effusions is still challenging. 
Measuring soluble biomarkers in pleural effusions could be an aid in diagnosis. Syndecan-1 
can be shed into biological fluids and might have conflicting roles as membrane-bound in 
cancer. Further, syndecan-1 could be either tumor suppressor or promoter in different cancer 
types [201]. 
In paper II, we explored the differential diagnostic and prognostic value of soluble syndecan-
1 in patients’ serum and pleural effusions from benign and malignant effusions including: 
lung cancer, breast cancer, ovarian and fallopian cancers, other malignancies, cancer of 
unknown primary, and MPM. Osteopontin is an established malignancy marker, which was 
used as a control. 
In pleural effusions, both syndecan-1 and osteopontin levels were higher in malignancies than 
benign conditions and the difference was even more pronounced for syndecan-1. However, 
this discriminatory performance was not seen in sera either for soluble syndecan-1 or 
osteopontin. Among the pleural malignancies, in all malignancies except for ovarian and 
fallopian carcinoma, syndecan-1 expression was higher in pleural effusions compared to 
benign disease. While, there was no significant difference in syndecan-1 in serum of these 
patients (Figure 1 and 2 in paper II).  
To investigate the diagnostic value of soluble syndecan-1, ROC curve was created. 
Syndecan-1 true positive rate (sensitivity) was plotted over its false positive rate (100% - 
specificity), and the area under this curve (AUC) will give us a measure of the syndecan-1’s 
overall accuracy. Soluble syndecan-1 in pleural effusion showed diagnostic value for 
malignancy from the benign cases, while in sera, syndecan-1 showed poor prediction of a 
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malignant disease (Figure 3 in paper II). Both sensitivity and specificity of syndecan-1 in 
pleural effusions was slightly higher than osteopontin (Table 2 in paper II). 
To study the prognostic value of soluble syndecan-1 Kaplan-Meier analysis were used. In 
pleural effusion of patients with pleural metastases, lower syndecan-1 levels than 
235.1 ng/mL resulted in longer survivals compared to patients with higher syndecan-1. The 
same results were seen with effusion osteopontin levels with a cut off of 6143 ng/mL. 
Stratifying MM patients in “low” and “high” syndecan-1 level in pleural effusions using a 
cutoff of 100.2 ng/mL demonstrated longer survival times of low syndecan-1 levels compared 
to high levels. Similar results were seen for effusion osteopontin levels with a cut off of 1630 
ng/mL (Figure 4 in paper II).  
The difference seen in pleural effusions, and not in sera can be explained by less interference 
by liver metabolism or elimination by the kidneys and also the lower contribution of other 
body fluids into pleural effusions, these effusions are known to have higher diagnostic 
accuracy than serum for several MM biomarkers [38, 202] 
Syndecan-1 ectodomain can act as soluble receptor for biological effectors such as growth 
factors and chemokines, therefore syndecan-1 shedding is important in regulating signaling 
pathways and possibly cancer progression and affecting patient’s survival [108, 115]. 
However, it is noteworthy that increased level of soluble syndecan-1 could be due to tumor 
burden as well and in this way affecting survivals. 
Taken together, this study shows that effusion content of syndecan-1 has diagnostic and 
prognostic values and combining syndecan-1 with other biomarkers to diagnose pleural 
malignancies could be advantageous. However, the use of syndecan-1 measurement in serum 
is limited for such performance. 
4.3 PAPER III: Syndecan-1 alters heparan sulfate composition and signaling 
pathways in malignant mesothelioma 
Syndecan-1 binds a wide range of heparin-binding growth factors through its polysaccharide 
chains and modulates the availability, stability, and/or activity of these binding partners 
consequently affecting downstream signaling pathways [203, 204]. Therefore, studying HS 
chain modifications could be crucial in different tumor types. In paper I, we reported that at 
transcriptomic levels, several enzymes involved in HS sulfation modifications were affected 
by overexpressing syndecan-1 in mesothelioma. One of the highly-affected enzymes derived 
from that study, was sulfatase-1 which removes 6-O-sulfates from HS chains. Therefore, in 
paper III we investigated syndecan-1 overexpression effect on HS chain composition and 
affected signaling pathway members in mesothelioma. In addition, the correlation between 
soluble syndecan-1 and sulfatase-1 in pleural effusions of cancer patients was studied. 
To explore the effect of syndecan-1, the expression of important enzymes involved HS 
biosynthetic and modifying machinery was studied both at RNA and protein levels. The most 
highly affected enzyme at RNA level was sulfatase-1. In addition, expression of EXT1, 
NDST1, HS2ST1, HS6ST1, SULF1 and the sulfate donor synthase PAPSS1 were affected by 
syndecan-1 overexpression (Figure 1a in paper III). Since both EXT1 and NDST1 were 
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transcriptionally downregulated, we postulated a negative feed-back in the syndecan-1 
overexpressing cells which leads to slower heparin sulfate biosynthesis. 
Using antibodies against various sulfated saccharide motifs revealed that syndecan-1 
overexpressing cells contained HS chains with higher contents of 6-O- and N-sulfation 
(Figure 2 in paper III). The chromatographical analysis showed that syndecan-1 
overexpression decreased total amounts of HS in both medium and cell samples (Figure 4a, b 
in paper III). This could be due to slower HS biosynthetic machinery as explained above. 
Furthermore, we know from previous studies that overexpression of syndecan-1 could 
downregulate other HSPGs in a compensatory way [99, 205]. 
Despite decreased amount of HS chains due to syndecan-1 overexpression, the overall 
sulfation of these chains was higher, mainly in N- and 6-O-sulfation (Table 4 in paper III), 
and more in details 6-O-sulfated disaccharides were affected (Figure 4c in paper III). This is 
in line with low expression of sulfatase-1 in these cells.  
Studying the downstream effect of HS chains modification due to syndecan-1, on mitogen-
activated protein kinase (MAPK)-related components, we showed using two independent 
methods that EGFR was higher in syndecan-1 overexpressing cells compared to controls, but 
the difference did not reach statistical significance. Moreover, phosphorylation of protein 
kinase WNK1 which is known to be apoptosis inhibitor, and Akt 1/2/3, an important factor in 
the G1/S transition checkpoint were decreased in syndecan-1 overexpressing cells (Figure 6 
and 8 in paper III). Elevated levels of both total and phospho-ERK1/2, in cells overexpressing 
syndecan-1 was shown by both flow cytometry analysis and immunocytochemistry (Figure 7 
in paper III). The activity of transcription factor c-Jun which is necessary for the expression 
of cyclin D1 and G1/S progression was inhibited by syndecan-1 overexpression. The 
expression of ETS-1 transcription factor was increased, but its activity was not affected 
(Figure 9 and 10 in paper III). The elevated ETS1 levels with no changes in activity can lead 
to the conclusion that ETS-1 activation was inhibited via a signaling pathway independent of 
ERK1/2. All these inhibition of Akt 1/2/3, c-Jun, and ETS1 ultimately resulted in cell cycle 
arrest due to syndecan-1 overexpression (Figure 11 in paper III). 
Sulfatase-1 expression was low in malignant pleural effusions indicating a potential 
diagnostic role for this enzyme in pleural malignancies. However, no prognostic effect in 
pleural malignancies was found for sulfatase-1. In addition, there was a fair inversed but not 
significant correlation between soluble syndecan-1 and sulfatase-1 in pleural effusion of 
mesothelioma patients (Figure 12 in paper III). These finding together mirror the results from 
paper II, where we found high levels of syndecan-1 in pleural malignancies. 
4.4 PAPER IV: Syndecan-1 overexpressing mesothelioma cells inhibit 
proliferation, migration and tube formation of endothelial cells 
Angiogenesis is crucial in tumor development and mesothelioma progression. Poor survival 
in mesothelioma patients is associated with high microvascular density and angiogenesis-
related proteins have been implicated in adverse prognosis [78, 79, 206]. However, anti-
angiogenesis treatments have shown modest results in mesothelioma patients. Syndecan-1 
can affect angiogenesis by acting as a co-receptor for extracellular ligands such as VEGF and 
FGF [98, 207] and interacting with αvβ3 and αvβ5 and regulating angiogenesis by activation 
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of these integrins and insulin-like growth factor-1receptor (IGF-1R) forming a ternary 
receptor complex. This complex is present mainly on tumor cells and activated endothelial 
cells during angiogenesis [208]. Moreover, syndecan-1 ectodomain can get shed by 
sheddases and this process generates soluble syndecan-1 receptors, which can actively 
participate in angiogenesis.  
In this paper, we investigated the role of syndecan-1 in angiogenesis. First shed syndecan-1 
level was confirmed in the conditioned media from syndecan-1 overexpressing mesothelioma 
cells. The angiogenesis-related proteins of conditioned medium from syndecan-1 
overexpressing cells were determined. Several angiogenesis-related proteins were altered 
including pro-angiogenic Angiopoietin-1, fibroblast growth factor-4 (FGF-4), hepatocyte 
growth factor (HGF), neuroglin-1 beta-1(NRG1-β1), and anti-angiogenic protein tissue 
inhibitor of metalloproteinases-1 (TIMP-1) and pro/anti-angiogenic proteins such as 
thrombospondin-1 (TSP-1) and transforming growth factor beta-1 (TGF-β1) (Figure1 in 
paper IV). Conditioned medium from syndecan-1 overexpressing mesothelioma cells 
inhibited endothelial cell proliferation, migration and tubulogenesis (Figure 2, 3 and 5 in 
paper IV). Migratory capacity of endothelial cells in presence of syndecan-1 overexpressing 
cell conditioned media was tested via both wound healing and along with chemotactic 
gradient. Endothelial cell migration was inhibited in wound healing setting but chemotactic 
migration of endothelial cells was not changed in presence of conditioned medium from 
syndecan-1 overexpressing cells. 
This inhibition of angiogenic characteristic of endothelial cells show that shed syndecan-1 
and angiogenesis-related proteins in the conditioned media from syndecan-1 overexpressing 
cells can affect angiogenesis. 
To explore the role of shed syndecan-1 per se on the tube formation of endothelial cells, we 
silenced MMP-7 expression in mesothelioma cells. MMP7 has been shown to be the main 
cause of syndecan-1 shedding from lung epithelium in response to injury [123]. As an effect 
of MMP-7 silencing on syndecan-1 shedding we observed that syndecan-1 was decreased by 
nearly 30% in the MMP-7 silenced supernatant compared to scrambled control 
(Supplementary Fig. 2B in paper IV). Although, MMP-7 was not fully silenced, the activity 
of other syndecan-1 sheddases might still be present. The partial inhibition of syndecan-1 
shedding restored the tube formation inhibition by syndecan-1. Thus, it can be concluded that 
presence of shed syndecan-1 seems to be crucial for angiogenesis inhibition (Fig. 5C and D, 
Fig.6, and Supplementary Fig.1 in paper IV).   
Yes-associated protein (YAP) is an effector of Hippo pathway and gets normally degraded in 
the cytoplasm. In MM, NF2 inactivation results in nuclear localization of the YAP and its 
activation [209]. The nuclear localization of YAP promotes angiogenesis, proliferation and 
migration in cancer [210]. We showed that endothelial cells manifest slightly more 
cytoplasmic and less nuclear YAP in presence of conditioned media from syndecan-1 
overexpressing cells compared to control. This is in line with hampered endothelial migration 
by shed syndecan-1 that described above.  
VEGF is one prominent angiogenic factor, which is previously proposed as a biomarker of 
tumor progression and angiogenesis in malignant effusions. Study from pleural effusions 
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from mesothelioma patients showed that shed syndecan-1 is positively correlated with VEGF. 
In addition, mesothelioma patients with higher levels of VEGF in pleural effusions displayed 
shorter survivals (Figure 8 in paper IV). Results from paper II show that mesothelioma 
patients have higher levels of shed syndecan-1 in pleural effusions compared to benign cases. 
Taken together these data suggest that combining VEGF and shed syndecan-1 in pleural 
effusions could be helpful prognostic tool in mesothelioma patients.  
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5 GENERAL CONCLUSION 
5.1 MAJOR FINDINGS 
Paper I:  Genes and pathways modulated by syndecan-1 in mesothelioma 
 Syndecan-1 silencing and overexpression in mesothelioma cells greatly affect cellular 
signaling.  
 Syndecan-1 is functionally linked to cell proliferation. 
 Syndecan-1 overexpression shows larger impact on differentially expressed genes than 
syndecan-1 silencing. 
 Syndecan-1 overexpression affects the expression of growth factors and their cognate 
receptos, TGFβ signaling pathway-related members, and causes GAG modifications. 
Paper II: Syndecan-1 and diagnostic/prognostic value in pleural malignancies 
 Shed syndecan-1 in malignant pleural effusions is higher than benign conditions, 
therefore it carries diagnostic value. 
 Syndecan-1 is a better diagnostic/prognostic marker in pleural effusion than in serum. 
 Mesothelioma patients with higher syndecan-1 levels in pleural effusions show shorter 
survival time. 
Paper III: Syndecan-1 alters heparan sulfate chains and signaling pathways in 
mesothelioma 
 Syndecan-1 overexpression affects HS biosynthetic/modifying enzymes mainly 
downregulating sulfatase-1. 
 HS content was reduced due to syndecan-1 overexpression, but overall sulfation was 
increased. 
 As an effect of these changes in HS structure, syndecan-1 modulates PI3K and MAPK 
signaling pathways in mesothelioma cells, resulting in deregulation of cell cycle 
progression. 
 Pleural malignancies demonstrate lower sulfatase-1 in  pleural effusions compared to 
benign conditions, and sulfatase-1 level inversely correlates with soluble syndecan-1 
level.  
Paper IV: Syndecan-1 role in angiogenesis of mesothelioma 
 Syndecan-1 overexpression on mesothelioma cells change angiogenicity by affecting the 
growth factors gradient and inhibiting endothelial cells proliferation, migration and tube 
formation. 
 Mesothelioma patients with higher VEGF level in pleural effusions had shorter survivals. 
 VEGF level in pleural effusions from mesothelioma patients is positively correlated with 
soluble syndecan-1. 
 Combining VEGF with other biomarkers in pleural effusion could give a better 
prognostic evaluation in mesothelioma patients. 
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6 FUTURE PERSPECTIVE 
This thesis focuses on the new functional and clinical roles of syndecan-1 and related genes 
and pathways in MM. Although the primary hypotheses were addressed, there are findings 
which merit further investigation. 
In general, it is worthy to investigate the role of silenced syndecan-1 as complementary 
approach to overexpression, where the study has been conducted via syndecan-1 upregulation 
only. In addition, using different mesothelioma cell lines could highlight the general 
applicability of our findings.    
Differentially expressed genes due to syndecan-1 modulation represent functional categories 
such as angiogenesis, adhesion, migration and proliferation which motivate future in vivo 
investigation. Moreover, syndecan-1 seems to be a powerful suppressor of TGFβ pathway in 
mesothelioma, which needs more mechanistic studies. 
Future translational studies are needed to reveal the mechanism behind correlation between 
shed syndecan-1 levels and mesothelioma patients’ survival. Whether metalloproteinases are 
involved in this high level of soluble syndecan-1 in effusions or tumor burden and 
malignancy affect the amount of soluble and membrane-bound syndecan-1, remained to be 
answered more in details. In addition, to elucidate the relationship between cell-bound and 
shed syndecan-1, the number of mesothelioma samples should be increased. 
Prognostic role of sulfatase-1 could be evaluated with larger clinical material. Furthermore, 
the exact mechanism behind inhibitory role of sulfatase-1 per se on cell cycle progression 
remains to be disclosed. 
To elucidate the role of shed syndecan-1 in angiogenesis by a more potent inhibitor of 
syndecan-1 shedding than the used MMP7 silencing would worth to study. This can be done 
via simultaneous silencing of other important enzymes in syndecan-1 shedding, or syndecan-
1 immunoprecipitation from conditioned media from mesothelioma cells. 
The direct effect of mesothelioma on endothelial cells seems to be interesting in the context 
of YAP expression. This can be performed in 3D culture to simulate better the interaction 
between two cell types. 
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